Cargando…

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

Antihormonal and chemotherapy are standard treatments for nonorgan-confined prostate cancer. The effectivity of these therapies is limited and the development of alternative approaches is necessary. In the present study, we report on the use of the multikinase inhibitor sorafenib in a panel of prost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Su Jung, Erb, Holger H H, Hobisch, Alfred, Santer, Frédéric R, Culig, Zoran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Endocrinology 2012
Materias:	Regular Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353237/ https://www.ncbi.nlm.nih.gov/pubmed/22383427 http://dx.doi.org/10.1530/ERC-11-0298

Ejemplares similares

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
por: Santer, Frédéric R, et al.
Publicado: (2010)

Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells
por: Cronauer, M V, et al.
Publicado: (2000)

Interleukin‐4 induces a CD44(high)/CD49b(high) PC3 subpopulation with tumor‐initiating characteristics
por: Erb, Holger H.H., et al.
Publicado: (2018)

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
por: Culig, Z, et al.
Publicado: (1999)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
por: Culig, Zoran
Publicado: (2021)

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy
por: Santer, Frédéric R., et al.
Publicado: (2015)

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα(2) through IRF9
por: Erb, Holger H H, et al.
Publicado: (2013)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Regulation of expression of Na(+),K(+)-ATPase in androgen-dependent and androgen-independent prostate cancer
por: Blok, L J, et al.
Publicado: (1999)

Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis
por: Costa-Pereira, A P, et al.
Publicado: (1999)

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression
por: Baretton, G B, et al.
Publicado: (1999)

Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis
por: Costa-Pereira, A P, et al.
Publicado: (2000)

The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells
por: Gruber, Martina, et al.
Publicado: (2019)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Prostate cancer treated by anti-androgens: is sexual function preserved?
por: Schröder, F H, et al.
Publicado: (2000)

p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
por: Gruber, Martina, et al.
Publicado: (2020)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion
por: Li, Yirong, et al.
Publicado: (2008)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
por: Culig, Zoran, et al.
Publicado: (2012)

CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
por: Bratt, O, et al.
Publicado: (1999)

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
por: Erb, Holger H. H., et al.
Publicado: (2020)

Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells
por: Sommer, Ulrich, et al.
Publicado: (2022)

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling
por: Nappo, G, et al.
Publicado: (2017)

Editorial: Heterogeneity and plasticity of prostate cancer
por: Culig, Zoran, et al.
Publicado: (2023)

Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer
por: Sidiropoulos, M, et al.
Publicado: (2001)

Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model
por: Miyake, H, et al.
Publicado: (2001)

Effects of Sorafenib on C-Terminally Truncated Androgen Receptor Variants in Human Prostate Cancer Cells
por: Zengerling, Friedemann, et al.
Publicado: (2012)

Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours
por: Dart, D Alwyn, et al.
Publicado: (2009)

The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity
por: Siciliano, Tiziana, et al.
Publicado: (2022)

Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells
por: Feiersinger, Gertrud E., et al.
Publicado: (2018)

Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue
por: Sommer, Ulrich, et al.
Publicado: (2022)

Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer
por: Lu, Zongliang, et al.
Publicado: (2021)

mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
por: Schiewer, Matthew J, et al.
Publicado: (2012)

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
por: Vakhrusheva, Olesya, et al.
Publicado: (2022)

Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.
por: Culig, Z., et al.
Publicado: (1998)

Resveratrol inhibits proliferation and promotes apoptosis via the androgen receptor splicing variant 7 and PI3K/AKT signaling pathway in LNCaP prostate cancer cells
por: Ye, Mushi, et al.
Publicado: (2020)

Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells
por: Amantini, Consuelo, et al.
Publicado: (2015)

Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival
por: Yang, Qing, et al.
Publicado: (2005)

Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma
por: Ito, Y, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_hqpjbnuve3ns2ltv7qv0qmga4d